A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GvHD with allogenic mesenchymal stem cells (MSC) from adipose tissue

      Chronic graft–versus–host disease (cGvHD) is the object of intense clinical research. Mesenchymal stromal cells (MSC) are known to have immunomodulatory effects. Using MSC from adipose tissue (AT–MSC) entails advantages, such as accessibility and procedural ease for obtaining large numbers of MSC, compared with bone marrow.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect